COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.


Weill Cornell Medicine, Hematology/Oncology, New York, NY. Electronic address: [Email]


The phase III COMPARZ study showed noninferior efficacy of pazopanib versus sunitinib in advanced renal cell carcinoma. In this COMPARZ post hoc analysis we characterized pazopanib responders, patient subgroups with better outcomes, and the effect of dose modification on efficacy and safety.


First-line,Sunitinib,Tyrosine kinase inhibitor,VEGF,VEGFR,

OUR Recent Articles